atai Life Sciences (ATAI) Competitors

MoonLake Immunotherapeutics (NASDAQ:MLTX) and atai Life Sciences (NASDAQ:ATAI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Which has preferable valuation and earnings, MLTX or ATAI?

MoonLake Immunotherapeutics has higher earnings, but lower revenue than atai Life Sciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than atai Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$118.94M	-$2.78	-19.74
atai Life Sciences	$1.86M	431.22	-$149.27M	-$0.91	-4.41

Does the media prefer MLTX or ATAI?

In the previous week, MoonLake Immunotherapeutics had 11 more articles in the media than atai Life Sciences. MarketBeat recorded 16 mentions for MoonLake Immunotherapeutics and 5 mentions for atai Life Sciences. atai Life Sciences' average media sentiment score of -0.04 beat MoonLake Immunotherapeutics' score of -0.34 indicating that atai Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
atai Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, MLTX or ATAI?

MoonLake Immunotherapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, atai Life Sciences has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

Do analysts prefer MLTX or ATAI?

MoonLake Immunotherapeutics currently has a consensus price target of $74.43, indicating a potential upside of 35.62%. atai Life Sciences has a consensus price target of $11.25, indicating a potential upside of 180.55%. Given atai Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe atai Life Sciences is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
atai Life Sciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.40

Do insiders & institutionals hold more shares of MLTX or ATAI?

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 28.4% of atai Life Sciences shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 26.8% of atai Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is MLTX or ATAI more profitable?

MoonLake Immunotherapeutics' return on equity of -40.98% beat atai Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-40.98%	-35.81%
atai Life Sciences	N/A	-102.10%	-77.55%

Summary

atai Life Sciences beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.